Open AccessRacial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses
Author(s) -
Monica Peravali,
Cristiane Gomes-Lima,
Eshetu Tefera,
Mairead Baker,
Mamta Sherchan,
Saira Farid,
Kenneth D. Burman,
Florina Constantinescu,
Irina Veytsman
Publication year - 2021
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v12.i2.103
Subject(s) - medicine , immune system , adverse effect , immunology , oncology
Immune checkpoint inhibitors (ICPi) cause various immune-related adverse events ( irAE) with thyroid dysfunction as a commonly reported abnormality. There is increasing evidence showing positive association with development of irAE and survival. However, prior trials with ICPi had underrepresentation of minorities with < 5% African Americans.